Shijiazhuang Yiling Pharmaceutical Co., Ltd. (002603.SZ)
CNY 16.29
(-0.12%)
CNY 16.29
(-0.12%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.77 Billion CNY | -43.11% |
| 2022 | 2.82 Billion CNY | 80.33% |
| 2021 | 1.56 Billion CNY | 9.11% |
| 2020 | 1.43 Billion CNY | 102.49% |
| 2019 | 710.17 Million CNY | -1.22% |
| 2018 | 718.95 Million CNY | 10.74% |
| 2017 | 649.24 Million CNY | 4.1% |
| 2016 | 623.68 Million CNY | 24.98% |
| 2015 | 499.03 Million CNY | 21.72% |
| 2014 | 409.99 Million CNY | 50.06% |
| 2013 | 273.22 Million CNY | 45.16% |
| 2012 | 188.22 Million CNY | -61.56% |
| 2011 | 489.58 Million CNY | 41.61% |
| 2010 | 345.71 Million CNY | 1.79% |
| 2009 | 339.63 Million CNY | 125.87% |
| 2008 | 150.37 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 11.96 Million CNY | -95.57% |
| 2024 Q1 | 362.8 Million CNY | 187.63% |
| 2024 Q2 | 270.15 Million CNY | -25.54% |
| 2023 Q3 | 190.35 Million CNY | -60.47% |
| 2023 Q4 | -414.01 Million CNY | -317.5% |
| 2023 Q1 | 1.45 Billion CNY | 35.66% |
| 2023 Q2 | 481.49 Million CNY | -66.95% |
| 2023 FY | 1.6 Billion CNY | -43.11% |
| 2022 Q3 | 454.12 Million CNY | -36.76% |
| 2022 Q2 | 718.07 Million CNY | 23.07% |
| 2022 Q1 | 583.45 Million CNY | 392.78% |
| 2022 Q4 | 1.07 Billion CNY | 136.48% |
| 2022 FY | 2.82 Billion CNY | 80.33% |
| 2021 FY | 1.56 Billion CNY | 9.11% |
| 2021 Q1 | 825.18 Million CNY | 262.27% |
| 2021 Q2 | 322.62 Million CNY | -60.9% |
| 2021 Q3 | 302.86 Million CNY | -6.12% |
| 2021 Q4 | 118.39 Million CNY | -60.91% |
| 2020 Q3 | 357.62 Million CNY | 8.48% |
| 2020 Q4 | 227.78 Million CNY | -36.31% |
| 2020 FY | 1.43 Billion CNY | 102.49% |
| 2020 Q1 | 522.96 Million CNY | 2136.83% |
| 2020 Q2 | 329.66 Million CNY | -36.96% |
| 2019 Q3 | 142.52 Million CNY | -28.87% |
| 2019 Q1 | 343.9 Million CNY | 648.38% |
| 2019 Q2 | 200.37 Million CNY | -41.74% |
| 2019 Q4 | 23.37 Million CNY | -83.6% |
| 2019 FY | 710.17 Million CNY | -1.22% |
| 2018 Q3 | 140.6 Million CNY | -20.59% |
| 2018 FY | 718.95 Million CNY | 10.74% |
| 2018 Q1 | 355.32 Million CNY | 220.06% |
| 2018 Q2 | 177.06 Million CNY | -50.17% |
| 2018 Q4 | 45.95 Million CNY | -67.32% |
| 2017 Q1 | 260.39 Million CNY | 142.96% |
| 2017 Q3 | 131.4 Million CNY | -10.27% |
| 2017 FY | 649.24 Million CNY | 4.1% |
| 2017 Q4 | 111.01 Million CNY | -15.51% |
| 2017 Q2 | 146.43 Million CNY | -43.76% |
| 2016 FY | 623.68 Million CNY | 24.98% |
| 2016 Q1 | 216.97 Million CNY | 90.87% |
| 2016 Q2 | 152.56 Million CNY | -29.69% |
| 2016 Q3 | 146.97 Million CNY | -3.66% |
| 2016 Q4 | 107.17 Million CNY | -27.08% |
| 2015 Q1 | 149.36 Million CNY | 80.82% |
| 2015 Q4 | 113.67 Million CNY | -4.18% |
| 2015 Q3 | 118.63 Million CNY | 1.1% |
| 2015 Q2 | 117.35 Million CNY | -21.43% |
| 2015 FY | 499.03 Million CNY | 21.72% |
| 2014 Q4 | 82.6 Million CNY | -11.8% |
| 2014 FY | 409.99 Million CNY | 50.06% |
| 2014 Q2 | 114.81 Million CNY | -3.45% |
| 2014 Q1 | 118.91 Million CNY | 719.24% |
| 2014 Q3 | 93.66 Million CNY | -18.42% |
| 2013 Q4 | 14.51 Million CNY | -81.78% |
| 2013 FY | 273.22 Million CNY | 45.16% |
| 2013 Q1 | 83.64 Million CNY | 397.18% |
| 2013 Q2 | 95.4 Million CNY | 14.06% |
| 2013 Q3 | 79.66 Million CNY | -16.5% |
| 2012 FY | 188.22 Million CNY | -61.56% |
| 2012 Q1 | 93.38 Million CNY | -40.86% |
| 2012 Q2 | 65.79 Million CNY | -29.54% |
| 2012 Q3 | 12.21 Million CNY | -81.43% |
| 2012 Q4 | 16.82 Million CNY | 37.71% |
| 2011 Q1 | 92.72 Million CNY | -19.37% |
| 2011 Q2 | 110.52 Million CNY | 19.2% |
| 2011 Q3 | 128.44 Million CNY | 16.21% |
| 2011 Q4 | 157.88 Million CNY | 22.92% |
| 2011 FY | 489.58 Million CNY | 41.61% |
| 2010 Q3 | 102.16 Million CNY | 0.0% |
| 2010 Q4 | 114.99 Million CNY | 12.56% |
| 2010 FY | 345.71 Million CNY | 1.79% |
| 2009 FY | 339.63 Million CNY | 125.87% |
| 2008 FY | 150.37 Million CNY | 0.0% |